Modern pharmacological approach for the management of heart failure

A tétel rövid nézete
dc.contributor.advisorPriksz, Dániel
dc.contributor.advisordeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorAmaefule , Chidera Nora
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentUjhelyi, Zoltán
dc.contributor.opponentKozma, Mariann
dc.contributor.opponentdeptGyógyszerésztudományi Kar::Gyógyszertechnológiai Tanszék
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.date.accessioned2025-07-28T13:56:08Z
dc.date.available2025-07-28T13:56:08Z
dc.date.created2025
dc.description.abstractHeart failure is a clinical syndrome that encompasses numerous etiologies and pathophysiological mechanisms rather than being a singular disease. This disease remains a significant global health challenge, which necessitates continual advancements in its treatment approaches. This review explores the evolution of pharmacological strategies in HF management, comparing traditional therapies with contemporary approaches. By compiling findings from historical and recent clinical guidelines and notable studies, this thesis highlights the transition from conventional agents such as digitalis, organomercurial diuretics, thiazides and more to newer evidence-based treatment steps. With the adoption of classification of HF according to stages and LVEF, notable developments including the incorporation of guideline-directed medical therapy have been invaluable. According to Bozkurt, 2024 on his paper on “Contemporary pharmacological treatment and management of heart failure”, initial treatment of patients with HFrEF includes foundational agents like ACEI/ARBs, angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists and most notably sodium-glucose cotransporter 2 (SGLT2) inhibitors. For patients with HFmrEF and HFpEF, their treatment includes SGLT2 inhibitors and diuretics. There also has been an emphasis on timely initiation of treatment with patients in pre-HF stages, and also the tailoring of treatment according to specific patient needs. These new therapy guidelines have demonstrated substantial benefits in reducing cardiovascular mortality, improving quality of life, and slowing disease progression. This review stresses the importance of personalised pharmacological approach as the cornerstone of modern heart failure care.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent41 pages
dc.identifier.urihttps://hdl.handle.net/2437/396207
dc.language.isoen
dc.rights.infoHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectHeart Failure
dc.subjectPharmacological treatment
dc.subjectModern therapies
dc.subject.dspaceMedicine
dc.titleModern pharmacological approach for the management of heart failure
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
Amaefule Chidera Nora 2025 FINAL.docx.pdf
Méret:
2.9 MB
Formátum:
Adobe Portable Document Format
Leírás:
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Medicine)